Category - Developments

Mateon Therapeutics (OTCQX:MATN) terminated its Phase 2/3 FOCUS after a third scheduled interim analysis of CA4P in combination with bevacizumab (Avastin) and physician’s choice chemotherapy in patients with platinum...

The FDA has approved Arkis BioSciences’ CerebroFlo external ventricular drain (EVD) catheter that includes Interface Biologics’ Endexo technology. The CerebroFlo catheter has demonstrated a 99% reduction in thrombus...

American CryoStem (OTC:CRYO) has expanded its relationship with Health Innovative Technology (HIT) of Hong Kong. After more than two years as CryoStem’s licensee in Hong Kong, HIT has licensed the patent rights to...

The HydRx Farms subsidiary of Scientus Pharma has received its Access to Cannabis for Medical Purposes Regulations (ACMPR) license from Health Canada. Scientus now is permitted to begin cultivating medicinal cannabis at...

Arbutus Biopharma’s (NASDAQ:ABUS) lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals (NASDAQ:ALNY), announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for...

MaRS Innovation and Evotec AG (FSE:EVT) have launched LAB150, a Toronto-based partnership to tap infrastructure and drug discovery expertise of Evotec and drug discovery projects from the 15-member institutions of MaRS...

Microbix Biosystems (TSX:MBX) has made its first full-scale shipment of antigen, produced using its new bioreactor manufacturing process, following customer validation. Bioreactors offer the prospect for better process...

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a decision by the U.S. District Court for the District of Delaware determined that the process used to manufacture IntelGenx’s and Par Pharmaceutical’s...

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) announced that the board has formed a committee to identify a new chairman with relevant global experience to guide the company through the anticipated upcoming international...

The CBS affiliate in Boston, WBZ-TV, has aired a segment about the opioid crisis, featuring Probuphine, a six-month implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) that releases a steady dose of buprenorphine...